US 11,773,155 B2
Bispecific antibody against rabies virus, and application thereof
Zhigang Liu, Beijing (CN); Xiaobo Hao, Beijing (CN); Yulan Liu, Beijing (CN); and Jingjing Guo, Beijing (CN)
Assigned to Beijing Wisdomab Biotechnology Co., ltd, Beijing (CN); GENRIX (Shanghai) Biopharmaceutical Co., Ltd., Shanghai (CN); and Chongqing GENRIX Biopharmaceutical Co., Ltd., Chongqing (CN)
Appl. No. 17/57,100
Filed by Beijing Wisdomab Biotechnology Co., Ltd, Beijing (CN); GENRIX (Shanghai) Biopharmaceutical Co. Ltd., Shanghai (CN); and Chongqing GENRIX Biopharmaceutical Co., Ltd., Chongqing (CN)
PCT Filed Aug. 1, 2019, PCT No. PCT/CN2019/098836
§ 371(c)(1), (2) Date Nov. 19, 2020,
PCT Pub. No. WO2020/029860, PCT Pub. Date Feb. 13, 2020.
Claims priority of application No. 201810901518.0 (CN), filed on Aug. 9, 2018.
Prior Publication US 2021/0340224 A1, Nov. 4, 2021
Int. Cl. C07K 16/10 (2006.01); A61P 31/14 (2006.01); C07K 16/46 (2006.01)
CPC C07K 16/10 (2013.01) [A61P 31/14 (2018.01); C07K 16/468 (2013.01); C07K 2317/31 (2013.01); C07K 2317/33 (2013.01); C07K 2317/55 (2013.01); C07K 2317/565 (2013.01); C07K 2317/622 (2013.01); C07K 2317/76 (2013.01)] 9 Claims
 
1. A bispecific antibody comprising two antigen-binding fragments that bind to epitope I and epitope III of rabies virus G protein respectively, wherein the bispecific antibody has the activity of neutralizing rabies virus,
wherein the antigen-binding fragment that binds to epitope I of rabies virus G protein comprises:
HCDR1 having the amino acid sequence of RYTIN (SEQ ID NO: 42), HCDR2 having the amino acid sequence of GIIPIFGTANYAQRFQG (SEQ ID NO: 43), HCDR3 having the amino acid sequence of ENLDNSGTYYYYFSGWFDP (SEQ ID NO: 44), LCDR1 having the amino acid sequence of TGTSSDIGAYDYVS (SEQ ID NO: 45), LCDR2 having the amino acid sequence of DATKRPS (SEQ ID NO: 46), LCDR3 having the amino acid sequence of CSYAGDYTPGVV (SEQ ID NO: 47); or
HCDR1 having the amino acid sequence of RYSIN (SEQ ID NO: 48), HCDR2 having the amino acid sequence of GIIPIFGTANYAQRFQG (SEQ ID NO: 43), HCDR3 having the amino acid sequence of ENLDNSGTYYYYFSGWFDP (SEQ ID NO: 44), LCDR1 having the amino acid sequence of TGTSSDIDGYDFVS (SEQ ID NO: 49), LCDR2 having the amino acid sequence of DATKRPS (SEQ ID NO: 46), LCDR3 having the amino acid sequence of CSYAGDYTPGVV (SEQ ID NO: 47); or
HCDR1 having the amino acid sequence of GYTIN (SEQ ID NO: 50), HCDR2 having the amino acid sequence of GIIPIFGTANYAQRFQG (SEQ ID NO: 43), HCDR3 having the amino acid sequence of ENLDNSGTYYYYFSGWFDP (SEQ ID NO: 44), LCDR1 having the amino acid sequence of TGTSSDLGGYDFVS (SEQ ID NO: 51), LCDR2 having the amino acid sequence of DATKRPS (SEQ ID NO: 46), LCDR3 having the amino acid sequence of CSYAGDYTPGVV (SEQ ID NO: 47); and
wherein the antigen-binding fragment that binds to epitope III of rabies virus G protein comprises:
HCDR1 having the amino acid sequence of SYGMH (SEQ ID NO: 52), HCDR2 having the amino acid sequence of TISYDGSIKDYADSVKG (SEQ ID NO: 53), HCDR3 having the amino acid sequence of GDRTGNLDY (SEQ ID NO: 54), LCDR1 having the amino acid sequence of RASQNIRNALN (SEQ ID NO: 55), LCDR2 having the amino acid sequence of DASTRQS (SEQ ID NO: 56), LCDR3 having the amino acid sequence of QQNSEFPPT (SEQ ID NO: 57);
wherein the HCDR and LCDR amino acid sequences are defined according to Kabat.